Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “EUGENOL”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 55 records · Page 3Linked to original sources
PubMed1994

Inhibition of microsomal lipid peroxidation and monooxygenase activities by eugenol.

Previously we reported that eugenol (4-allyl-2-methoxyphenol) inhibits non-enzymatic peroxidation in liver mitochondria (E. Nagababu and N. Lakshmaiah, 1992, Biochemical Pharmacology. 43, 2393-2400). In the present study, we examined the effect of eugenol on microsomal mixed function oxidase mediated peroxidation using Fe+3-ADP-NADPH, carbon tetrachloride (CCL4)-NADPH and cumene hydroperoxide (CumOOH) systems. In the presence of eugenol the formation of thiobarbituric acid reactive substances (TBARS) was decreased in all the systems (IC50 values: 14 microM for Fe+3-ADP-NADPH, 4.0 microM for CCl4-NADPH and 15 microM for CumOOH). Oxygen uptake was also inhibited to a similar extent with Fe+3-ADP-NADPH and CumOOH systems. A comparative evaluation with other antioxidants showed that in Fe+3-ADP-NADPH and CumOOH systems, the antioxidant efficacy was in the order: butylated hydroxytoluene (BHT) > eugenol > alpha-tocopherol, while in CCl4-NADPH system the order was alpha-tocopherol > BHT > eugenol. Time course of inhibition by eugenol indicated interference in initiation as well as propagation of peroxidation. Eugenol did not inhibit cytochrome P-450 reductase activity but it inhibited P-450 - linked monooxygenase activities such as aminopyrine-N-demethylase, N-nitrosodimethylamine demethylase, benzo(a)pyrene hydroxylase and ethoxyresorufin-O-deethylase to different extents. However, CumOOH supported monooxygenases (aminopyrine-N-demethylase and benzo(a)pyrene hydroxylase) required much higher concentrations of eugenol for inhibition. The concentration of eugenol required to inhibit monooxygenase activities was more than that required to inhibit peroxidation in all the systems. Eugenol elicited type 1 changes in the spectrum of microsomal cytochrome P-450. These results suggest that the inhibitory effect of eugenol on lipid peroxidation is predominantly due to its free radical quenching ability. Eugenol significantly protected against the degradation of cytochrome P-450 during lipid peroxidation with all the systems tested. These findings suggest that eugenol has the potential to be used as a therapeutic antioxidant. Further evaluation may throw more light on this aspect.

Aminopyrine N-Demethylase↗
PubMed2002

Antioxidant and prooxidant action of eugenol-related compounds and their cytotoxicity.

To clarify the possible link between radicals and the cytotoxicity of eugenol-related compounds, 2-allyl-4-X-phenols (2-allyl-4-chlorophenol (1), 2-allyl-4-phenylphenol (2), 2-allyl-4-methoxyphenol (3), 2-allyl-4-acetylphenol (4), 2-allyl-4-nitrophenol (5), 2-allyl-4-t-butylphenol (6), 2-allyl-4-methyphenol (7), 2-allyl-4-bromophenol (8), 2,4-dimethoxyphenol (9)), and dimeric compounds from eugenol (4-allyl-2-methoxyphenol), BHA (2-t-butyl-4-methoxyphenol) or MMP (2-methoxy-4-methylphenol); bis-EUG (3,3'-dimethoxy-5,5'-di-2-propenyl-1, 1'-biphenyl-2,2'-diol) (10), bis-MMP (3,3'-dimethoxy-5,5'-dimethyl-1,1'-biphenyl-2,2'-diol) (11) bis-BHA (3,3'-di-t-butyl-5,5'-dimethoxy-1,1'-biphenyl-2,2'-diol) (12) were synthesized. The radical production, radical-scavenging activity and the cytotoxicity of these synthetic compounds and conventional antioxidants (i.e. butylhydroxytoluine, BHT; butylhydroxyanisole, BHA; alpha-tocopherol (alpha-Toc); eugenol, phenol) were studied. Erectron spin resonance (ESR) spectroscopy suggested that compounds of 3, 6, 9, eugenol and BHA, but not compounds of 10, 11, and 12 produced radicals in alkaline solutions (pH>9.5) and compounds, 3, eugenol and 9 most efficiently scavenged reactive oxygen species (ROS, O(2)(-)). The cytotoxic activity of 6 toward human submandibular gland carcinoma (HSG) cells was the highest and was 1000-fold greater than that of eugenol and 100-fold greater than that of BHA, possibly due to the high hydrophobicity and stable phenoxy radicals of this compound. The kinetic polymerization method in the presence of methyl methacrylate (MMA), an antioxidant, and 2,2'-azobisisobutyronitrile (AIBN) was developed for the measurements of the number of moles of peroxy radicals trapped by moles of the relative phenols (stoichiometric factors, n), the inhibition rate of polymerization (R(inh)), and the inhibition rate constants (k(inh), the rate constants for scavenging of radicals by an antioxidant). The n values of conventional phenolic antioxidants decreased in the order: alpha-Toc>BHT>eugenol>phenol. Those for eugenol and phenol, less hindered phenols, were much less than two, whereas those for alpha-Toc and BHT, hindered phenols, were approximately two. The R(inh) of alpha-Toc significantly increased tcompared with that of BHT, eugenol and phenol. The k(inh) of the polymer radicals of the MMA reaction with conventional phenolic antioxidants was a low value of 1-2x10(2) M(-1) s(-1), suggesting that the antioxidants trapped radicals quickly. The comparative cytotoxicity of methoxyphenols against HSG cells was investigated. The cytotoxic activity of dimers of 10 and 12 was markedly lower than that of their corresponding monomers, whereas that of the dimer of MMP, 11 was not reduced even after the dimerization. In particular, visible-light (VL) exposure enhanced the cytotoxicity of 11 similar to the monomers of eugenol, BHA and MMP. Changes in BDE (ph(O-H)) (homolytic bond dissociation energy) for phenols is well known to be associated with the n and k(inh) values, and consequently the cytotoxic activity. Thus, the BDE was calculated using a PM3 semiempirical method. The n and k(inh) values for monophenols, but not for dimers were correlated to the BDE, possibly due to the steric hindrance of orthosubstituents of dimers. The quantitative structure-activity relationship (QSAR) of eugenol-related compounds was investigated, indicating that logP (octanol-water partition coefficients), the redox potential measured in culture medium, was effective as a term for QSAR. A parabolic relation between the cytotoxic activity and the logP or the redox potential, but not the BDE was observed with an optimum value. In conclusion, the cytotocity of eugenol-related compounds was significantly associated with the activity of the production of phenoxyl radicals, their stability of the subsequent quinonemethide (QM) and the hydrophobicity.

Animals↗
PubMed1996

Effect of short-term dietary administration of eugenol in humans.

1. In order to study the antigenotoxic potential of eugenol in humans, ten healthy non-smoking males ingested a daily amount of 150 mg eugenol or the placebo for seven consecutive days. After a washout period of one week, groups ingesting eugenol or the placebo were crossed and received the other treatment for seven consecutive days. 2. On days 8 and 22 blood samples were taken for the assessment of standard clinical biochemical parameters. To study the possible antigenotoxic effect of eugenol, on day 8 and 22 blood samples were collected and exposed in vitro to the established genotoxic agents mitomycin C and vinblastine. After exposure the percentage of cells with chromosome aberrations and micronuclei was determined in cultured white blood cells. On days 8 and 22 paracetamol (500 mg p.o.) was administered as test substance to measure phase-II biotransformation capacity. Glutathione-S-transferase (GST) activities were determined in erythrocytes and blood plasma. 3. No significant differences in the clinical biochemical parameters were detected between the eugenol-period and the placebo-period, indicating that daily administration of 150 mg eugenol for 7 days has no toxic affects. 4. No significant differences on the cytogenetic parameters were found after ingestion of eugenol. Thus, there are no indications for an antigenotoxic potential of eugenol in humans, consuming daily 150 mg eugenol for 7 days. 5. A significant reduction in alpha-class GSTs in plasma (P < 0.05), but not in the other measured biotransformation parameters, was found in volunteers during the eugenol-periods as compared to the placebo-period. This may either reflect GST-inhibition by eugenol or protection against background damage of liver cells by eugenol.

Acetaminophen↗
PubMed2000

Effect of eugenol-containing sealer on marginal adaptation of dentine-bonded resin fillings.

AIM: Eugenol is claimed to interfere with the polymerization of composite resins and to affect shear bond strengths of dentine-bonded composite restorations. Eugenol-based sealers are used during root canal treatment in teeth that may require build-ups or extensive restorations. Unfortunately, the adverse effect of eugenol has mostly been assessed in shear bond tests and this variable may be clinically inappropriate. The current study evaluate the effect of eugenol in a eugenol-based endodontic sealer on marginal adaptation of composite resin restorations with and without thermo-mechanical stress. METHODOLOGY: Thirty Class V cavities with half of the cavity margins in dentine and half of the cavity margins in enamel were prepared in extracted human premolars and then divided into 5 groups. Teeth in group 1 were not contaminated with eugenol. Cavities in groups 2-4 were contaminated with a eugenol-based sealer (Tubli-Seal, Kerr) and cleaned with: (i) sandblasting, (ii) bur finishing alone or (iii) bur finishing combined with swabbing with alcohol. These 4 groups were temporized for 6 weeks (Ketac, ESPE), whilst group 5 received no eugenol, was not temporized and acted as the control. Cavities were restored with Tetric Ceram using Syntac Classic (Vivadent) as a dentine-bonding agent. The specimens were then thermo-mechanically stressed. The percentages of marginal adaptation in dentinal and enamel margins were assessed in a SEM at x200 magnification before and after stress using a replica method. Mean percentages of marginal adaptation were calculated and compared using a two way-ANOVA (influence of eugenol and cleaning procedure) and non-parametric tests. RESULTS: Marginal adaptation in enamel exceeded 95% and 92% in all specimens before and after thermo-mechanical stress, respectively. Before stress, marginal adaptation in dentine ranged from 92.3 +/- 7.9% to 95.7 +/- 6.2% in groups 1-5. After stress, the percentage of marginal adaptation in dentine decreased significantly overall (P < 0.05, range 39.8 +/- 21.1% to 82.9 +/- 13.7%). The effect of contamination with eugenol was not significant (P > 0.05): in contrast, there was a significantly beneficial effect when the entire cavity was finished with burs (P < 0.01). CONCLUSIONS: Under the conditions of this study, the eugenol containing sealer did not significantly impair marginal adaptation in dentinal margins of mixed Class V restorations when bur finishing was employed before placement. However, no other cleaning method was sufficient to produce acceptable figures of marginal adaptation.

Analysis of Variance↗
PubMedDate not supplied

Metabolic activation of eugenol by myeloperoxidase and polymorphonuclear leukocytes.

Eugenol has recently been associated with the toxic effects of clove cigarettes on human lungs. We have studied the metabolism and adverse effects of eugenol on human polymorphonuclear leukocytes (PMNs). Myeloperoxidase, isolated and purified from human PMNs, catalyzed the oxidation of eugenol to a reactive intermediate which is likely to be a quinone methide. Eosinophil peroxidase, lactoperoxidase, prostaglandin H synthase, horseradish peroxidase, and rat intestinal peroxidase also supported this hydrogen peroxide dependent reaction. Glutathione inhibited the formation of this metabolite, resulting in the formation of glutathione disulfide and a small amount of eugenol-glutathione conjugates. In cellular incubations, phorbol ester stimulated PMNs catalyzed the covalent binding of [3H]eugenol to cellular protein, which was partially inhibitable by azide. Intracellular glutathione levels decreased by 90% over a period of 30 min in phorbol ester stimulated PMNs exposed to 100 microM eugenol compared with decreases of 30% (phorbol ester alone) or 5% (eugenol alone) in control incubations. In addition, eugenol was more cytotoxic to PMNs in the presence of phorbol ester than in its absence, and eugenol inhibited the phorbol ester stimulated oxidative burst in PMNs as reflected by a decrease in oxygen consumption, superoxide formation, and hydrogen peroxide formation. These results suggest that PMNs are capable of activating eugenol to a reactive intermediate and also suggest a mechanism whereby eugenol can potentially interfere with and adversely affect vital PMN functions.

Biotransformation↗
PubMed1992

Inhibitory effect of eugenol on non-enzymatic lipid peroxidation in rat liver mitochondria.

The anti-peroxidative activity of eugenol on Fe(2+)-ascorbate- and Fe(2+)-H2O2-induced lipid peroxidation was studied using rat liver mitochondria. Eugenol inhibited thiobarbituric acid reactive substance (TBARS) formation induced by both the systems in addition to oxygen uptake and mitochondrial swelling induced by Fe(2+)-ascorbate. Time course studies on TBARS formation indicated the ability of eugenol to inhibit initiation and propagation reactions. There was no measurable chemical modification of eugenol during the course of mitochondrial peroxidation by both the systems. Mitochondrial peroxidation by Fe(2+)-H2O2 was inhibited by hydroxyl radical (OH) scavengers like mannitol, benzoate, formate and dimethyl sulfoxide apart from eugenol. The OH scavenging ability of eugenol was evident from its inhibitory effect on OH-mediated deoxyribose degradation. The second-order rate constant for the reaction of OH with eugenol was about 4.8 x 10(10) M-1 sec-1. Eugenol reduced Fe3+ ions and Fe3+ chelated to citrate or ADP but it did not exhibit pro-oxidant activity in OH-mediated deoxyribose degradation. Incubation of mitochondria with eugenol resulted in the uptake of small but significant quantities of eugenol which inhibited subsequent lipid peroxidation by acting as a chain breaking antioxidant.

Animals↗
PubMed1991

Metabolism and cytotoxicity of eugenol in isolated rat hepatocytes.

The metabolism and toxic effects of eugenol (4-allyl-2-methoxyphenol) were studies in isolated rat hepatocytes. Incubation of hepatocytes with eugenol resulted in the formation of conjugates with sulfate, glucuronic acid and glutathione. The major metabolite formed was the glucuronic acid conjugate. Covalent binding to cellular protein was observed using [3H]eugenol. Loss of intracellular glutathione and cell death were also observed in these incubations. Concentrations of 1 mM eugenol caused a loss of over 90% of intracellular glutathione and resulted in approximately 85% cell death over a 5-h incubation period. The loss of the majority of glutathione occurred prior to the onset of cell death (2 h). The effects of eugenol were concentration dependent. The addition of 1 mM N-acetylcysteine to incubations containing 1 mM eugenol was able to completely prevent glutathione loss and cell death as well as inhibit the covalent binding of eugenol metabolites to protein. Conversely, pretreatment of hepatocytes with diethylmaleate to deplete intracellular glutathione increased the cytotoxic effects of eugenol. These results demonstrate that eugenol is actively metabolized in hepatocytes and suggest that the cytotoxic effects of eugenol are due to the formation of a reactive intermediate, possibly a quinone methide.

Animals↗
PubMed1996

Inhibition of rat, mouse, and human glutathione S-transferase by eugenol and its oxidation products.

The irreversible and reversible inhibition of glutathione S-transferases (GSTs) by eugenol was studied in rat, mouse and man. Using liver cytosol of human, rat and mouse, species differences were found in the rate of irreversible inhibition of GSTs by eugenol in the presence of the enzyme tyrosinase. Tyrosinase was used to oxidize eugenol. No inhibition was observed in the absence of tyrosinase. The rate of irreversible inhibition of GSTs was highest in mouse cytosol, and lowest in rat cytosol. In addition, the irreversible inhibition of human and rat GSTs by eugenol was studied using purified isoenzymes of man and rat. The human GST isoenzymes A1-1, M1a-1a and P1-1 and the rat GST isoenzymes 1-1, 2-2, 3-3, 4-4 and 7-7 were irreversibly inhibited by eugenol in the presence of tyrosinase. In this respect human GST P1-1 and rat GST 7-7 were by far the most sensitive enzymes; human GST A2-2 was not inhibited. Indications were found that human GST P1-1 may be inhibited via three mechanisms: in addition to the well documentated nucleophilic addition of quinones and oxidation of cysteine residues, a covalent subunit cross-linking was also observed. The reversible inhibition of human and rat GST by eugenol, eugenol methyl ether, isoeugenol methyl ether, 2-allylphenol and 4-propylphenol was also studied using purified isoenzymes. The reversible inhibition of human and rat GSTs, using 1-chloro-2,4-dinitrobenzene as substrate, was expressed as I25. All compounds caused moderate reversible inhibition (I25 ranged from 0.2 to 5.4 mM for human GSTs and from 0.4 to 4.9 mM for rat GSTs). In rat, eugenol methyl ether was the strongest inhibitor. In human, the overall inhibiting capacities of eugenol, eugenol methyl ether, isoeugenol methyl ether and 4-propyl phenol were more or less similar; 2-allylphenol was the poorest inhibitor.

Allyl Compounds↗
PubMed2004

Copper-mediated oxidative DNA damage induced by eugenol: possible involvement of O-demethylation.

Eugenol used as a flavor has potential carcinogenicity. DNA adduct formation via 2,3-epoxidation pathway has been thought to be a major mechanism of DNA damage by carcinogenic allylbenzene analogs including eugenol. We examined whether eugenol can induce oxidative DNA damage in the presence of cytochrome P450 using [32P]-5'-end-labeled DNA fragments obtained from human genes relevant to cancer. Eugenol induced Cu(II)-mediated DNA damage in the presence of cytochrome P450 (CYP)1A1, 1A2, 2C9, 2D6, or 2E1. CYP2D6 mediated eugenol-dependent DNA damage most efficiently. Piperidine and formamidopyrimidine-DNA glycosylase treatment induced cleavage sites mainly at T and G residues of the 5'-TG-3' sequence, respectively. Interestingly, CYP2D6-treated eugenol strongly damaged C and G of the 5'-ACG-3' sequence complementary to codon 273 of the p53 gene. These results suggest that CYP2D6-treated eugenol can cause double base lesions. DNA damage was inhibited by both catalase and bathocuproine, suggesting that H2O2 and Cu(I) are involved. These results suggest that Cu(I)-hydroperoxo complex is primary reactive species causing DNA damage. Formation of 8-oxo-7,8-dihydro-2'-deoxyguanosine was significantly increased by CYP2D6-treated eugenol in the presence of Cu(II). Time-of-flight-mass spectrometry demonstrated that CYP2D6 catalyzed O-demethylation of eugenol to produce hydroxychavicol, capable of causing DNA damage. Therefore, it is concluded that eugenol may express carcinogenicity through oxidative DNA damage by its metabolite.

8-Hydroxy-2'-Deoxyguanosine↗
PubMed2005

A comparative study of the antioxidant/prooxidant activities of eugenol and isoeugenol with various concentrations and oxidation conditions.

Eugenol (compound in , 4-allyl-2-methyoxyphenol) and isoeugenol (compound in , 4-propenyl-2-methoxyphenol), both used as a flavor agent in cosmetic and food products, have both prooxidant and antioxidant activities. Their adverse effects such as allergic and inflammatory reaction may be due to their prooxidant activity. To clarify the mechanisms of their cytotoxicity and the factors affecting their antioxidant/prooxidant activities, we investigated the cytotoxicity, ROS production, and cellular glutathione (GSH) levels induced by eugenol and isoeugenol in a human submandibular cell line. The cytotoxicity (MTT method) of eugenol was 1 order of magnitude lower than that of isoeugenol (CC50: eugenol, 0.395 mM; isoeugenol, 0.0523 mM); and ROS production (CDF staining) was induced significantly by isoeugenol, but not by eugenol. Under treatment with H2O2 (100 microM) plus horseradish peroxidase (1 microg/ml) for 30 min or with visible light irradiation for 5 min, eugenol caused biphasic ROS production characterized by enhanced at lower eugenol concentrations (5-10 microM) and decreased at higher concentrations (500 microM). In contrast, isoeugenol enhanced ROS production over a wide range of concentrations (5-500 microM). Isoeugenol at 1000 microM significantly reduced GSH levels compared with eugenol at the same concentration. The high cytotoxicity of isoeugenol may be attributed to its induction of high ROS production and low GSH levels, possibly as a result of benzyl radical formation. In contrast, the cytotoxicity of eugenol is likely to be mediated by ROS-independent mechanisms, possibly involving phenoxyl radicals and/or eugenol quinone methide.

Antioxidants↗
PubMed1997

Action of eugenol as a retarder against polymerization of methyl methacrylate by benzoyl peroxide.

This study was undertaken to examine an effect of eugenol on polymerization of methyl methacrylate (MMA) by benzoyl peroxide (BPO) and 2,2'-azobisisobutyronitrile (AIBN) in the presence of eugenol. The induction period and initial rate of polymerization (IRP) were determined from polymerization curves of MMA using differential scanning calorimetry (DSC). The induction period increased with increasing concentration of eugenol in both BPO and AIBN systems. The IRP decreased as the concentration of eugenol in both BPO and AIBN systems. The IRP decreased as the concentration of eugenol increased. Its decreasing rate in the BPO system was higher than that in the AIBN system. In the BPO system, the IRP was reduced to zero at 0.5 mol% of eugenol. Eugenol in the BPO system was an efficient retarder, although the decrease in IRP was relatively small, below 0.05 mol%. Eugenol was an inhibitor even at high concentration in the AIBN system. The suppressible effect of eugenol appears to be due to the interaction between free radicals from BPO and eugenol.

Benzoyl Peroxide↗
PubMed2004

Eugenol causes melanoma growth suppression through inhibition of E2F1 transcriptional activity.

Metastatic malignant melanoma is an extremely aggressive cancer, with no currently viable therapy. 4-Allyl-2-methoxyphenol (eugenol) was tested for its ability to inhibit proliferation of melanoma cells. Eugenol but not its isomer, isoeugenol (2-methoxy-4-propenylphenol), was found to be a potent inhibitor of melanoma cell proliferation. In a B16 xenograft study, eugenol treatment produced a significant tumor growth delay (p = 0.0057), an almost 40% decrease in tumor size, and a 19% increase in the median time to end point. More significantly, 50% of the animals in the control group died from metastatic growth, whereas none in the treatment group showed any signs of invasion or metastasis. Eugenol was well tolerated as determined by measurement of bodyweights. Examination of the mechanism of the antiproliferative action of eugenol in the human malignant melanoma cell line, WM1205Lu, showed that it arrests cells in the S phase of the cell cycle. Flow cytometry coupled with biochemical analyses demonstrated that eugenol induced apoptosis. cDNA array analysis showed that eugenol caused deregulation of the E2F family of transcription factors. Transient transfection assays and electrophoretic mobility shift assays showed that eugenol inhibits the transcriptional activity of E2F1. Overexpression of E2F1 restored about 75% of proliferation ability in cultures. These results indicate that deregulation of E2F1 may be a key factor in eugenol-mediated melanoma growth inhibition both in vitro and in vivo. Since the E2F transcription factors provide growth impetus for the continuous proliferation of melanoma cells, these results suggest that eugenol could be developed as an E2F-targeted agent for melanoma treatment.

Animals↗
PubMed2006

Mechanisms of cytotoxicity of eugenol in human osteoblastic cells in vitro.

AIM: To evaluate the mechanisms of cytotoxicity of eugenol in human osteoblastic cells in vitro. METHODOLOGY: Cytotoxicity and cell proliferation assays were performed to elucidate the toxic effects of eugenol on the human osteoblastic cell line U2OS. Furthermore, the effects of antioxidants catalase (scavenger of H2O2), superoxide dismutase (SOD, an extracellular superoxide free radical scavenger) and N-acetyl-L-cysteine (NAC, a cell-permeable glutathione precursor) were added to discover the possible mechanisms of eugenol-induced cytotoxicity. Paired Student's t-test was applied for the statistical analysis of the results. RESULTS: Eugenol demonstrated a cytotoxic effect to U2OS cells in a dose-dependent manner (P < 0.05). The 50% inhibition concentration of eugenol was approximately 0.75 mmol L(-1). Eugenol also inhibited cell proliferation during a 4-day culture period (P < 0.05). Addition of NAC extracellularly protected the cells from eugenol-induced cytotoxicity (P < 0.05). Neither, SOD nor catalase provided any protective effects on eugenol-induced cytotoxicity (P > 0.05). CONCLUSIONS: The levels of eugenol tested inhibited growth and proliferation of U2OS cells. Eugenol has significant potential for periapical toxicity. These inhibitory effects were associated with glutathione levels.

Acetylcysteine↗
PubMed1998

Role of endothelium and adventitia on eugenol-induced relaxation of rabbit ear artery precontracted by histamine.

Eugenol (> or = 0.1 mM) inhibited the contractions induced by various stimulants, such as 90 mM extracellular K+ solution ([K+]0), histamine and noradrenaline in the rabbit ear artery. Inhibitory actions of eugenol occurred in a concentration-dependent manner, however, eugenol more dominantly inhibited the histamine-induced contraction than those induced by either 90 mM [K+]0 solution or noradrenaline. Removal of both endothelium and adventitia did not change the inhibitory actions of eugenol on the 90 mM [K+]0- and noradrenaline-induced contractions, however, attenuated those on the histamine-induced contraction. Chlorphenylamine abolished the histamine-induced contraction, but neither cimetidine, ranitidine nor thioperamide modified the eugenol actions on the contractions induced by histamine. Pretreatment with nitric oxide syntheses inhibitor NG-nitro-L-arginine (LNNA; 100 microM), but not soluble guanylate cyclase inhibitor methylene blue (MB; 10 microM), prevented endothelium/adventitia-dependent augmentation of the eugenol-induced relaxation on the histamine-induced contraction. When an intact tissue, but not an endothelium/adventitia-denuded tissue, was placed at the up-stream close to the other denuded preparation (test preparation), histamine-induced contraction observed in the test preparation tended to be augmented. Similarly, eugenol-induced relaxation was also augmented by the same treatment. Eugenol (0.3 mM) inhibited the excitatory junction potentials (EJPs) without hyperpolarization of the membrane. However, a high concentration of eugenol (1 mM) slightly hyperpolarized the membrane (ca. 5 mV). No transient enhancement of amplitude of EJP was recorded. These results suggest that eugenol may inhibit the histamine-induced muscle contraction directly, and the inhibition is augmented by the adventitia and endothelium partly by vasoactive substances, which were released from the adventitia/endothelium-derived substances in rabbit ear artery.

Animals↗
PubMed1995

The protective effects of eugenol on carbon tetrachloride induced hepatotoxicity in rats.

Our earlier studies in vitro have shown that eugenol inhibits liver microsomal monooxygenase activities and carbon tetrachloride (CCl4)-induced lipid peroxidation (Free Rad. Res. 20, 253-266, 1994). The objective of the present investigation was to study the in vivo protective effect of eugenol against CCl4 toxicity. Eugenol (5 or 25 mg/kg body wt) given orally for 3 consecutive days did not alter the levels of serum glutamic oxalacetic transaminase (SGOT), microsomal enzymes such as cytochrome P450 reductase, glucose-6-phosphatase (G-6-Pase) xenobiotic-metabolizing enzymes (aminopyrine-N-demethylase, N-nitrosodimethylamine-demethylase and ethoxyresorufin-O-deethylase) and liver histology. Doses of eugenol (5 or 25 mg/kg) administered intragastrically to each rat on three consecutive days i.e. 48 hr, 24 hr and 30 min before a single oral dose of CCl4 (2.5 ml/kg body wt) prevented the rise in SGOT level without appreciable improvement in morphological changes in liver. Eugenol pretreatment also did not influence the decrease in microsomal cytochrome P450 content, G-6-Pase and xenobiotic-metabolizing enzymes brought about by CCl4. Since eugenol is metabolized and cleared rapidly from the body, the dose schedule was modified in another experiment. Eugenol (0.2, 1.0, 5.0 or 25 mg/kg) when given thrice orally i.e. prior to (-1 hr) along with (0 hr) and after (+3 hr) the i.p. administration of CCl4 (0.4 ml/kg) prevented significantly the rise in SGOT activity as well as liver necrosis. The protective effect was more evident at 1 mg and 5 mg eugenol doses. However, the decrease in microsomal G-6-Pase activity by CCl4 treatment was not prevented by eugenol suggesting that the damage to endoplasmic reticulum is not protected. The protective effect of eugenol against CCl4 induced hepatotoxicity is more evident when it is given concurrently or soon after rather than much before CCl4 treatment.

Animals↗
PubMed1989

Mechanism of inhibition of prostaglandin H synthase by eugenol and other phenolic peroxidase substrates.

The mechanism of inhibition of prostaglandin H synthase (PHS) by eugenol was investigated using purified apoenzyme reconstituted with either manganese protoporphyrin IX (Mn-PHS) or hematin (Fe-PHS). Eugenol stimulated Fe-PHS activity at low concentrations and inhibited at higher concentrations, an activity typical of many phenolic compounds. Eugenol was also an excellent reducing cosubstrate for the peroxidase, being cooxidized to a reactive quinone methide in the process. Higher concentrations of eugenol were required to inhibit Fe-PHS than Mn-PHS (which retains cyclooxygenase activity but not peroxidase activity). Inhibition by eugenol was highly dependent on arachidonic acid concentration. In experiments using Mn-PHS, eugenol increased the time required for the initiation of O2 consumption after addition of arachidonic acid and also inhibited the rate of O2 uptake. Eugenol did not, however, affect the total amount of O2 consumed. The addition of 10 microM hydroperoxide (prostaglandin G2) to these incubations did not prevent the inhibitory effects of eugenol. Other phenolic compounds, including guaiacol, butylated hydroxyanisole, and acetaminophen inhibited Mn-PHS in a manner similar to eugenol. These results demonstrate that eugenol and other phenolic compounds specifically inhibit the cyclooxygenase component of PHS and that this inhibition occurs in addition to, or independent of, the effect of these compounds on peroxide tone or their peroxidative metabolism. We suggest that this inhibition is due to competition with arachidonic acid for the active site of PHS.

Animals↗
PubMed1996

Effect of eugenol on the mutagenicity of benzo[a]pyrene and the formation of benzo[a]pyrene-DNA adducts in the lambda-lacZ-transgenic mouse.

To study the possible reduction by eugenol of the mutagenicity and genotoxicity of benzo[a]pyrene (B[a]P) in vivo, the lambda-lacZ-transgenic mouse strain 40.6 (Muta Mouse) was used. Male mice were fed a diet containing 0.4% (w/w) eugenol or a control diet for 58 days. On day 10, half of the mice received an i.p. dose of 100 mg/kg b.w. B[a]P. The lacZ mutants were recovered by packaging of DNA isolated from liver into lambda phage, and expressed in E. coli C lacZ-recA-galE- bacteria. In both control mice and mice fed the eugenol diet, B[a]P treatment resulted in a similar, significant increase in lacZ mutant frequency. Eugenol was not mutagenic by itself. By 32P-postlabelling analysis of the liver DNA using an analysis method with chromatographic conditions for B[a]P-DNA adducts, no effect of eugenol on the formation of B[a]P-DNA adducts in the lambda-lacZ-transgenic mouse was found. By 32P-postlabelling analysis using an alkenylbenzene solvent system the amount of B[a]P-DNA adducts was lower in mice fed the eugenol diet than in mice fed the control diet but the decrease was not statistically significant. However, one spot indicative of an eugenol-associated DNA adduct was detected. The present data provide no evidence for antimutagenic or antigenotoxic potential of eugenol in vivo. Furthermore, they suggest genotoxicity in vivo of eugenol per se.

Animals↗
PubMed1994

Eugenol triggers different pathobiological effects on human oral mucosal fibroblasts.

Pathobiological effects of eugenol (4-allyl-2-methoxyphenol), a major constituent of betel quid (BQ), were studied on oral mucosal fibroblasts. At a concentration higher than 3 mmol/L, eugenol was cytotoxic to oral mucosal fibroblasts in a concentration- and time-dependent manner. Cell death was associated with intracellular depletion of glutathione (GSH). Most of the GSH was depleted prior to the onset of cell death. At concentrations of 3 mmol/L and 4 mmol/L, eugenol depleted about 45% and 77% of GSH after one-hour incubation. In addition, eugenol decreased cellular ATP level in a concentration- and time-dependent manner. Eugenol also inhibited lipid peroxidation. Inhibition of lipid peroxidation was partially explained by its dose-dependent inhibition of xanthine oxidase activity. The IC50 of eugenol on xanthine oxidase activity was about 0.3 mmol/L. No DNA strand break activity for eugenol was found at concentrations between 0.5 and 3 mmol/L. Taken together, frequent exposure of oral mucosa to a high concentration of eugenol during the chewing of BQ might be involved in the pathogenesis of oral submucous fibrosis and oral cancer via its cytotoxicity. In contrast, eugenol at a concentration less than 1 mmol/L might protect cells from the genetic attack of reactive oxygen species via inhibition of xanthine oxidase activity and lipid peroxidation.

Adenosine Triphosphate↗